Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Phase 1 Evaluation of MaaT033 in Hematology Patients (CIMON)
NCT04150393Phase 1Completed
- Sponsor
- MaaT Pharma
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MaaT-033 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by MaaT Pharma. Primary endpoint: Occurrence of MaaT033-related, treatment-emergent (serious) adverse events, grade >3 up to 10 weeks. Started Oct 2020; status: completed.
02
Drugs
MaaT-033
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04150393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150393.